Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,206 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study.
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, Lewis DJ, Sureda Balari A, Cunningham D, Oliveri RS, Elliott B, DeMarco D, Azaryan A, Chiu C, Li T, Chen KM, Ahmadi T, Lugtenburg PJ. Hutchings M, et al. Among authors: cunningham d. Lancet. 2021 Sep 25;398(10306):1157-1169. doi: 10.1016/S0140-6736(21)00889-8. Epub 2021 Sep 8. Lancet. 2021. PMID: 34508654 Clinical Trial.
BCL-2 antisense therapy in patients with non-Hodgkin lymphoma.
Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z. Webb A, et al. Among authors: cunningham d. Lancet. 1997 Apr 19;349(9059):1137-41. doi: 10.1016/s0140-6736(96)11103-x. Lancet. 1997. PMID: 9113013 Clinical Trial.
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I, Harries M, Cunningham D, Hill M, Ross PJ, Archer CD, Norman AR, Wotherspoon A, Koh DM, Gill K, Uzzell M, Prior Y, Catovsky D. Chau I, et al. Among authors: cunningham d. Br J Haematol. 2003 Mar;120(6):970-7. doi: 10.1046/j.1365-2141.2003.04226.x. Br J Haematol. 2003. PMID: 12648066 Free article. Clinical Trial.
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma.
Rao S, Watkins D, Cunningham D, Dunlop D, Johnson P, Selby P, Hancock BW, Fegan C, Culligan D, Schey S, Morris TC, Lissitchkov T, Oliver JW, Holmlund JT. Rao S, et al. Among authors: cunningham d. Ann Oncol. 2004 Sep;15(9):1413-8. doi: 10.1093/annonc/mdh359. Ann Oncol. 2004. PMID: 15319248 Free article. Clinical Trial.
2,206 results